Northern Trust Corp Grows Stock Holdings in Solventum Corporation $SOLV

Key Points

• Northern Trust Corp increased its stock holdings in Solventum Corporation by 3.3%, owning approximately 1.04% of the company valued at $137.5 million after purchasing an additional 58,373 shares.
• Recent reports from analysts, including upgrades from Morgan Stanley, set a target price for Solventum shares as high as $103.00, with a consensus rating of Hold.
• Solventum reported a $1.69 EPS for the last quarter, surpassing estimates by $0.24, and forecasted 6.58 EPS for the current year.

Northern Trust Corp grew its stake in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 3.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,807,674 shares of the company's stock after acquiring an additional 58,373 shares during the period. Northern Trust Corp owned 1.04% of Solventum worth $137,456,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Rossby Financial LCC purchased a new stake in shares of Solventum during the first quarter worth $25,000. Strengthening Families & Communities LLC lifted its position in shares of Solventum by 376.8% during the first quarter. Strengthening Families & Communities LLC now owns 329 shares of the company's stock worth $25,000 after acquiring an additional 260 shares in the last quarter. Clarity Asset Management Inc. purchased a new stake in shares of Solventum during the fourth quarter worth $25,000. Raiffeisen Bank International AG purchased a new stake in shares of Solventum during the fourth quarter worth $29,000. Finally, Hara Capital LLC purchased a new stake in shares of Solventum during the first quarter worth $38,000.

Solventum Price Performance

NYSE SOLV traded up $0.01 during trading hours on Wednesday, reaching $72.93. 392,696 shares of the stock traded hands, compared to its average volume of 1,079,850. The stock has a 50 day simple moving average of $73.76 and a two-hundred day simple moving average of $72.84. Solventum Corporation has a 1 year low of $59.35 and a 1 year high of $85.92. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The company has a market cap of $12.64 billion, a price-to-earnings ratio of 33.77, a price-to-earnings-growth ratio of 1.76 and a beta of 0.52.

Solventum (NYSE:SOLV - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, beating analysts' consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.12 billion. During the same quarter last year, the business posted $1.56 earnings per share. The company's revenue for the quarter was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, analysts predict that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SOLV has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Solventum from a "strong-buy" rating to a "buy" rating in a research report on Sunday. KeyCorp began coverage on Solventum in a research report on Friday, June 6th. They issued a "sector weight" rating on the stock. Argus upgraded Solventum from a "hold" rating to a "buy" rating and set a $90.00 price objective on the stock in a research report on Tuesday, July 1st. Morgan Stanley upgraded Solventum from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $94.00 price objective (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Solventum has a consensus rating of "Hold" and a consensus price target of $85.75.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.